Cedazuridine and decitabine FDA Approval Status (2026) – Approved or Not?
FDA Regulatory Database

Is Cedazuridine and decitabine
FDA approved?

DrugStatusIndex.com provides a plain-English status page for Cedazuridine and decitabine, including FDA approval status, prescription classification, compounding context, pricing information, and regulatory notes.

FDA Approved
FDA status
Hypomethylating Agent Combination / Blood Cancer
Drug category
https://www.goodrx.com/inqovi
Last reviewed
Drug status summary

Cedazuridine and decitabine

FDA Approved

Cedazuridine and decitabine is listed for DrugStatusIndex cancer drug review with a working oncology status of FDA approved or FDA-recognized use under approved labeling.

Brand names
Inqovi
Prescription status
Manufacturer or patient-assistance savings may apply for brand/specialty products
Compounded status
Commercial FDA-approved oncology products or approved generics may be available; compounding is generally not appropriate when approved products meet patient needs.
Confusion level
High
FDA Approved Approved for commercial use in the US
Not Approved Not cleared by FDA for use
Investigational Under review or in clinical trials
Rx Only Prescription required — not OTC
FDA approval status

Cedazuridine and decitabine approval status and regulatory context

This page is structured for LPagery Pro and uses your CSV fields to create a consistent, scalable drug-status page that matches the current DrugStatusIndex.com home page design.

What DrugStatusIndex currently shows

Cedazuridine and decitabine is listed for DrugStatusIndex cancer drug review with a working oncology status of FDA approved or FDA-recognized use under approved labeling.

Regulatory note: Cedazuridine and decitabine estimated cash pricing: $15,000-$20,000 / month. Discount/coupon estimate: $14,000-$18,000 specialty estimate. Pricing varies by dose, quantity, pharmacy, location, insurance, and current savings programs.
FDA status
FDA Approved
Drug category
Hypomethylating Agent Combination / Blood Cancer
Prescription status
Manufacturer or patient-assistance savings may apply for brand/specialty products
Availability note
Coverage and prior authorization vary by plan, dose, pharmacy, and diagnosis.

Index review fields

Review status
$15,000-$20,000 / month
Last checked
$14,000-$18,000 specialty estimate
Published
Yes
Page URL
https://drugstatusindex.com/is-cedazuridine-and-decitabine-fda-approved/
Pricing and access

Cedazuridine and decitabine pricing information

Pricing can vary by dose, pharmacy, insurance coverage, manufacturer savings, coupon programs, market availability, and current supply conditions.

Retail estimate
{pricing_retail_estimate}

Estimated cash or retail pricing range when available.

Coupon estimate
{pricing_coupon_estimate}

Discount-card or pharmacy coupon estimate when available.

Pricing last checked
{pricing_last_checked}

Pricing data should be rechecked before making financial or treatment decisions.

Pricing summary

{pricing_summary}

Coverage and savings notes

Manufacturer savings: {pricing_manufacturer_savings}

Insurance note: {pricing_insurance_note}

Sources and verification

Verify Cedazuridine and decitabine directly with trusted source material

DrugStatusIndex.com is an informational resource. FDA status, availability, and pricing should be independently verified using official FDA resources, pharmacy data, prescribing information, and licensed healthcare guidance.

FDA / regulatory source
https://www.cancer.gov/about-cancer/treatment/drugs/cancer-drugs
Pricing source
{pricing_source_url}

Preview this drug-status page

Use this button to preview the generated LPagery page for Cedazuridine and decitabine and confirm the page output before wider publishing.

Preview Page →
Informational resource only
DrugStatusIndex.com reflects publicly available FDA regulatory data and does not provide medical advice, diagnosis, treatment recommendations, pharmacy recommendations, or legal/regulatory advice. Always consult a licensed healthcare provider before making any medical decision.
Scroll to Top